PBH Stock Cash Flow Statements

Prestige Consumer Healthcare Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Prestige Consumer Healthcare Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2010-06-30	2005-06-30

operating activities
net income	47,466,000	50,128,000	61,032,000	54,377,000	49,068,000	49,458,000	53,046,000	53,559,000	53,276,000	51,951,000	51,023,000	55,272,000	52,086,000	50,215,000	45,325,000	57,755,000	35,514,000	40,873,000	44,589,000	43,706,000	37,046,000	38,058,000	33,252,000	33,925,000	-139,274,000	38,167,000	30,841,000	34,466,000	-39,687,000	314,793,000	30,705,000	33,759,000	11,090,000	31,641,000	32,195,000	-5,531,000	13,936,000	27,995,000	31,803,000	26,173,000	16,732,000	16,001,000	3,130,000	32,792,000	20,692,000	19,349,000	12,257,000	19,244,000	14,655,000	-15,000	9,510,000	12,949,000	14,768,000	9,605,000	4,007,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	7,666,000	7,252,000	6,868,000	7,929,000	8,124,000	7,843,000	7,646,000	7,643,000	7,543,000	8,130,000	8,248,000	8,384,000	8,485,000	8,050,000	7,963,000	7,594,000	7,537,000	7,609,000	7,551,000	7,467,000	7,331,000	7,381,000	7,222,000	7,061,000	7,526,000	7,887,000	7,994,000	8,372,000	8,045,000	8,340,000	8,534,000	8,507,000	7,092,000	5,852,000	6,016,000	6,832,000	6,198,000	6,071,000	5,687,000	5,720,000	2,961,000	3,277,000	3,647,000	3,294,000	3,268,000	3,285,000	3,359,000	3,296,000	3,295,000	3,051,000	2,563,000	2,570,000	2,550,000	2,547,000	2,635,000
loss on disposal of property and equipment			0	78,000	5,000		40,000			77,000	81,000	13,000		52,000	1,000	26,000		79,000	89,000	42,000		165,000	-1,000	20,000		160,000	36,000	1,000
deferred and other income taxes	5,827,000	7,131,000	2,914,000	3,752,000	612,000
amortization of debt origination costs	442,000	438,000	434,000	428,000	454,000	1,514,000	1,424,000	1,319,000	983,000	815,000	970,000	828,000	1,419,000	1,376,000	676,000	759,000	1,410,000	651,000	1,518,000	1,400,000	1,046,000	1,055,000	860,000	851,000	1,380,000	1,522,000	2,101,000	920,000	1,996,000	1,252,000	1,748,000	1,746,000	2,504,000	1,032,000	2,866,000	2,231,000	3,561,000	1,378,000	1,917,000	2,138,000
stock-based compensation costs	3,682,000	2,733,000	2,865,000	2,134,000	3,425,000	3,727,000	2,449,000	3,688,000	4,146,000	2,433,000	3,466,000	3,857,000	1,708,000	2,234,000	3,219,000	1,878,000	2,599,000	1,588,000	2,892,000	1,464,000	1,962,000	1,780,000	2,521,000	1,381,000	1,278,000	1,832,000	2,671,000	1,657,000	1,997,000	2,186,000	3,013,000	1,713,000	1,888,000	2,327,000	1,993,000	1,940,000	2,856,000	2,064,000	1,987,000	3,047,000	1,858,000	1,383,000	1,276,000	1,294,000	1,193,000	807,000	992,000	1,060,000	913,000	718,000	703,000	796,000	861,000	857,000
non-cash operating lease cost	1,947,000	1,925,000	1,892,000	1,724,000	1,706,000	1,655,000	1,678,000	1,572,000	1,244,000	1,713,000	1,491,000	1,493,000	1,672,000	1,683,000	1,660,000	1,691,000	1,720,000	1,775,000	1,756,000	1,831,000	2,669,000	2,963,000	1,816,000	1,338,000
changes in operating assets and liabilities:
accounts receivable	27,343,000	-25,201,000	-6,317,000	8,823,000	6,368,000	695,000	-11,432,000	-1,217,000	5,632,000	-8,802,000	-1,197,000	-7,079,000	-2,806,000	12,474,000	-18,443,000	-15,879,000	147,000	7,367,000	-10,376,000	39,734,000	-7,473,000	-1,358,000	174,000	5,808,000	-8,378,000	13,116,000	-3,361,000	-4,357,000	9,030,000	-4,728,000	-10,888,000	1,543,000	-6,564,000	-12,730,000	-4,795,000	5,151,000	-629,000	6,371,000	-6,496,000	2,578,000	6,956,000	1,240,000	14,207,000	-16,782,000	11,070,000	636,000	11,012,000	-15,316,000	-9,214,000	-10,038,000	-741,000	-5,660,000	585,000	2,078,000	11,404,000
inventories	-4,441,000	4,071,000	3,086,000	-3,423,000	-13,048,000	10,649,000	13,567,000	7,934,000	-7,711,000	-16,777,000	-7,395,000	-14,415,000	-13,987,000	1,672,000	3,594,000	9,384,000	1,703,000	-1,944,000	3,162,000	51,000	3,747,000	5,583,000	2,539,000	-8,939,000	546,000	-6,936,000	5,158,000	-9,303,000	-3,649,000	4,576,000	-510,000	-2,899,000	6,327,000	-5,926,000	-6,336,000	-4,327,000	4,109,000	-3,276,000	-3,627,000	-211,000	1,540,000	-588,000	-3,083,000	7,537,000	-6,716,000	-5,991,000	-447,000	-156,000	-2,748,000	7,560,000	2,822,000	-2,706,000	-3,966,000	1,086,000
prepaid expenses and other current assets	-10,946,000	-903,000	1,771,000	1,428,000	2,359,000	-5,609,000	1,209,000	1,367,000	-5,181,000	905,000	1,726,000	-3,227,000	7,070,000	-6,095,000	1,522,000	-1,049,000	-1,788,000	1,037,000	1,543,000	-4,019,000		2,249,000	1,207,000	-4,335,000		2,771,000	679,000	623,000		1,812,000	7,519,000	9,604,000		1,037,000	4,415,000	5,697,000	-13,393,000	2,036,000	4,958,000	-1,522,000	-2,203,000	653,000	-5,402,000	2,432,000	187,000	-2,705,000	245,000	5,550,000	6,000	-5,659,000	856,000	438,000	1,356,000	2,029,000
accounts payable	2,756,000	-560,000	-11,255,000	-8,187,000	591,000	-1,007,000	-5,144,000	-13,221,000	-5,599,000	7,876,000	-1,526,000	2,542,000	15,233,000	2,196,000	7,276,000	-15,551,000	18,447,000	-26,606,000	23,203,000	-32,386,000	12,301,000	-14,556,000	3,159,000	5,306,000	8,794,000	-16,974,000	-12,292,000	16,479,000	1,008,000	-19,044,000	16,032,000	-8,024,000	14,279,000	6,348,000	4,221,000	-3,401,000	6,205,000	-13,034,000	-5,302,000	783,000	-3,096,000	-3,356,000	-160,000	8,022,000	-9,147,000	10,552,000	-1,025,000	15,015,000	135,000	2,735,000	-1,202,000	1,032,000	2,562,000	-659,000
accrued liabilities	-813,000	2,625,000	3,775,000	2,645,000	-2,061,000	-8,485,000	4,032,000	-3,245,000	-8,519,000	-1,443,000	-736,000	10,524,000	-5,437,000	-9,517,000	6,131,000	18,439,000	-23,148,000	16,361,000	-19,713,000	11,588,000	-8,628,000	14,108,000	-1,000,000	7,616,000	-9,526,000	-1,079,000	13,992,000	347,000	-30,462,000	10,836,000	-10,311,000	-1,558,000	-19,826,000	15,718,000	10,239,000	-3,634,000	-6,535,000	6,650,000	5,693,000	-7,136,000	-3,212,000	1,472,000	-2,868,000	-4,882,000	-5,781,000	-2,577,000	1,281,000	9,199,000	-849,000	8,100,000	-1,854,000	5,317,000	-6,971,000	310,000
operating lease liabilities	-1,916,000	-1,909,000	-1,950,000	-1,888,000	-1,883,000	-1,875,000	-1,766,000	-1,748,000	-1,745,000	-1,740,000	-1,599,000	-1,602,000	-1,641,000	-1,657,000	-1,572,000	-1,578,000	-1,633,000	-1,639,000	-1,634,000	-1,812,000	-2,394,000	-3,032,000	-2,030,000	-1,368,000
other		2,399,000	-24,000	-20,000	-944,000					0	1,000	446,000					-8,791,000	1,055,000	-9,000	-109,000				-93,000	-301,000	0	355,000	-108,000
net cash from operating activities	79,013,000	61,848,000	65,091,000	69,800,000	54,776,000	66,907,000	71,472,000	62,460,000	48,087,000	54,942,000	57,540,000	58,247,000	63,126,000	66,297,000	61,194,000	69,305,000	59,087,000	49,227,000	52,139,000	75,154,000	56,126,000	57,998,000	50,223,000	52,777,000	50,847,000	43,330,000	39,255,000	55,852,000	54,438,000	47,132,000	54,419,000	54,121,000	7,424,000	40,066,000	49,531,000	50,751,000	37,899,000	45,861,000	47,069,000	43,521,000	29,671,000	30,722,000	25,262,000	32,800,000	22,798,000	36,729,000	40,502,000	45,632,000	14,742,000	19,459,000	14,527,000	18,023,000	15,443,000	20,713,000	9,812,000
capex	-838,000	-3,479,000	-1,566,000	-2,027,000	-1,152,000	-3,143,000	-1,996,000	-2,934,000	-1,477,000	-1,803,000	-2,376,000	-1,047,000	-3,161,000	-2,229,000	-2,752,000	-1,500,000	-4,896,000	-5,728,000	-9,066,000	-2,553,000	-5,505,000	-3,233,000	-3,866,000	-1,956,000	-3,341,000	-2,065,000	-2,605,000	-2,469,000	-2,876,000	-4,871,000	-2,231,000	-2,554,000	-1,042,000	-531,000	-509,000	-895,000	-1,028,000	-857,000	-903,000	-780,000	-496,000	-106,000	-339,000	-955,000	-1,364,000	-1,346,000	-3,656,000	-4,068,000	-1,198,000	-248,000	-51,000	-231,000	-76,000	-130,000	0
free cash flows	78,175,000	58,369,000	63,525,000	67,773,000	53,624,000	63,764,000	69,476,000	59,526,000	46,610,000	53,139,000	55,164,000	57,200,000	59,965,000	64,068,000	58,442,000	67,805,000	54,191,000	43,499,000	43,073,000	72,601,000	50,621,000	54,765,000	46,357,000	50,821,000	47,506,000	41,265,000	36,650,000	53,383,000	51,562,000	42,261,000	52,188,000	51,567,000	6,382,000	39,535,000	49,022,000	49,856,000	36,871,000	45,004,000	46,166,000	42,741,000	29,175,000	30,616,000	24,923,000	31,845,000	21,434,000	35,383,000	36,846,000	41,564,000	13,544,000	19,211,000	14,476,000	17,792,000	15,367,000	20,583,000	9,812,000
investing activities
purchases of property, plant and equipment	-838,000	-3,479,000	-1,566,000	-2,027,000	-1,152,000	-3,143,000	-1,996,000	-2,934,000	-1,477,000	-1,803,000	-2,376,000	-1,047,000	-3,161,000	-2,229,000	-2,752,000	-1,500,000	-4,896,000	-5,728,000	-9,066,000	-2,553,000	-5,505,000	-3,233,000	-3,866,000	-1,956,000	-3,341,000	-2,065,000	-2,605,000	-2,469,000	-2,876,000	-4,871,000	-2,231,000	-2,554,000
net cash (used in) investing activities	-1,938,000
financing activities
term loan repayments		0	-60,000,000	-40,000,000	-35,000,000	-75,000,000	-65,000,000	-55,000,000	-30,000,000	-15,000,000	-25,000,000	-15,000,000	-55,000,000	-50,000,000	-475,000,000	-20,000,000	-65,000,000	0	-74,000,000	-56,000,000	-27,000,000				-45,000,000	-55,000,000			-319,000,000	-20,000,000	-55,000,000	-50,000,000	-45,000,000	0	-80,500,000	-50,000,000	-10,000,000	0	-25,000,000	-25,000,000
payments of finance leases	-608,000	-2,637,000	-211,000	-968,000	-720,000	-715,000	-709,000	-704,000	-699,000	-689,000	-683,000	-686,000	-437,000	-649,000	-858,000	-638,000	-525,000	-206,000	-376,000	-336,000	-224,000
proceeds from exercise of stock options	3,155,000	2,462,000	8,748,000	1,617,000	1,975,000	7,271,000	1,635,000	2,155,000	7,028,000	5,684,000	0	1,489,000	1,322,000	3,011,000	503,000	2,204,000	1,527,000	39,000	69,000	1,216,000	317,000	463,000	269,000	275,000	0	1,903,000	148,000	880,000	154,000	0	1,033,000	433,000	584,000	21,000	18,000	3,405,000	89,000	202,000	70,000	6,328,000	1,294,000	169,000	595,000	4,834,000	309,000	569,000	5,380,000	0	80,000	317,000	1,000	8,000	563,000
fair value of shares surrendered as payment of tax withholding	-4,054,000	0	0	-31,000	-5,801,000	0	0	0	-5,508,000	-16,000	0	-5,450,000	0	0	0	-2,916,000	0	0	0	-1,242,000	0	-94,000	-81,000	-799,000	0	0	0	-2,281,000	0	0	-48,000	-1,027,000	0	-36,000	0	-1,395,000	-42,000	0	0	-2,187,000	-1,171,000	-466,000	0	0	-278,000
repurchase of common stock	-34,775,000	-11,313,000	-2,402,000	-11,818,000	-25,976,000	0	0	0	-25,000,000	0	-12,273,000	-37,727,000					-1,993,000	-8,877,000			-6,745,000	0	-21,210,000	-28,766,000	0	0	0	-49,978,000
net cash (used in) financing activities	-36,282,000
effects of exchange rate changes on cash and cash equivalents	825,000	129,000	-2,076,000	711,000	663,000	-605,000	1,415,000	-490,000	-140,000	798,000	-635,000	-1,142,000	449,000	-230,000	-868,000	-310,000	-283,000	1,045,000	893,000	1,942,000	-2,249,000	847,000	-472,000	-19,000	352,000	-406,000	-69,000	-283,000	-44,000	138,000	669,000	337,000	1,470,000	-1,482,000	363,000	-760,000	830,000	478,000	-893,000	82,000	104,000	57,000	-5,000	159,000	-3,000	-67,000	-1,000	38,000	-24,000	32,000	1,000	-30,000	-2,000
increase in cash and cash equivalents	41,618,000	47,010,000	-666,000			-17,146,000	3,548,000	5,487,000	-3,909,000	43,916,000	6,573,000	8,684,000			-120,806,000	131,322,000	-29,801,000	35,500,000	-31,338,000	-36,819,000	66,169,000	686,000	-1,137,000	1,512,000	2,858,000	-12,238,000	2,641,000	1,721,000	-12,828,000	2,399,000	-1,158,000	2,280,000	-21,434,000	32,831,000	1,581,000	1,647,000	-21,743,000	26,821,000	554,000	280,000	-12,656,000	-66,022,000	67,520,000	7,527,000	3,636,000						-3,522,000
cash and cash equivalents - beginning of period	97,884,000		0	0	46,469,000		0	0	58,489,000	0	0	27,185,000		0	0	32,302,000		0	0	94,760,000		0	0	27,530,000		0	0	32,548,000		0	0	41,855,000		0	0	27,230,000		0	0	21,318,000	28,331,000		0	0	15,670,000		0	0	19,015,000		0	0	13,334,000
cash and cash equivalents - end of period	139,502,000		-666,000	17,284,000	34,256,000		3,548,000	5,487,000	54,580,000	43,916,000	6,573,000	35,869,000		-21,800,000	-120,806,000	163,624,000		35,500,000	-31,338,000	57,941,000		686,000	-1,137,000	29,042,000		-12,238,000	2,641,000	34,269,000		2,399,000	-1,158,000	44,135,000		32,831,000	1,581,000	28,877,000		26,821,000	554,000	21,598,000	15,675,000		67,520,000	7,527,000	19,306,000		-18,575,000	24,602,000	4,404,000		-3,522,000	1,970,000	5,991,000
interest paid	11,501,000	10,377,000	11,876,000	11,881,000	13,670,000	13,582,000	15,960,000	16,124,000	17,582,000	17,700,000	15,454,000	3,562,000	25,085,000	17,798,000	15,092,000	3,389,000	33,363,000	4,504,000	36,852,000	5,571,000	25,861,000	18,272,000	28,067,000	19,966,000	28,277,000	20,808,000	28,240,000	20,907,000	24,793,000	24,375,000	25,106,000	24,298,000	30,594,000	17,356,000	18,922,000	18,337,000	20,265,000	18,317,000	18,106,000	22,444,000	13,867,000	14,771,000	18,070,000	14,690,000	14,826,000	15,492,000	17,625,000	18,133,000	18,391,000	6,474,000	12,713,000	2,589,000	13,201,000	3,182,000	8,051,000
income taxes paid	3,253,000	18,605,000	14,821,000	15,030,000	3,661,000	21,031,000	13,488,000	13,154,000	11,964,000	11,943,000	13,890,000	1,799,000	3,591,000	21,836,000	18,753,000	2,388,000	4,704,000	10,859,000	16,636,000	2,182,000	9,390,000	6,557,000	12,848,000	1,807,000	8,393,000	16,626,000	2,110,000	334,000	7,579,000	7,824,000	6,807,000	2,230,000	22,872,000	18,384,000	5,386,000	1,357,000	6,338,000	5,307,000	1,793,000	1,914,000	707,000	1,259,000	1,293,000	7,811,000	657,000	3,441,000	6,527,000	249,000	407,000	166,000	6,855,000	5,635,000	209,000	342,000	422,000
loss on sale or disposal of property and equipment
impairment loss
changes in operating assets and liabilities, net of effects from acquisition:
acquisitions and other
net cash from investing activities		-3,479,000	-9,816,000	-2,027,000	-2,130,000	-15,004,000	-4,496,000	-2,934,000	2,323,000	-1,803,000	-2,376,000	-1,047,000	-3,293,000	-20,229,000	-231,666,000	-1,323,000	-4,896,000	-5,728,000	-9,066,000	-2,553,000	-8,265,000	-2,483,000	-3,866,000	-1,956,000	-3,341,000	-2,065,000	63,307,000	-2,469,000	-2,876,000	-4,871,000	-2,231,000	-1,584,000	-804,881,000	59,262,000	51,919,000	-895,000	-228,012,000	6,380,000	-903,000	-436,000	-78,487,000	-106,000	-339,000	-56,169,000	-1,362,000	-1,346,000	18,044,000	-4,068,000	-1,409,000	-663,048,000	-51,000	969,000	-76,000	-130,000
borrowings under revolving credit agreement										0	0	20,000,000	0	0	0	85,000,000	0				55,000,000	15,000,000	15,000,000	15,000,000	0	15,000,000	10,000,000	20,000,000	10,000,000				90,000,000	0			100,000,000	0	0	15,000,000	65,000,000	0	0			0	15,000,000	8,000,000	25,000,000
repayments under revolving credit agreement										0	-10,000,000	-10,000,000	0	-20,000,000			0	-15,000,000	0	-55,000,000	0	-44,000,000	-41,000,000	-35,000,000	0	-15,000,000	-10,000,000	-20,000,000	-5,000,000				0	-65,000,000			-15,000,000	-26,100,000	-20,000,000	-35,000,000	-30,000,000	-37,500,000	-10,000,000	-17,500,000	-18,000,000	-7,000,000	0	0	-8,000,000
payment of debt costs
net cash from financing activities		-11,488,000	-53,865,000	-51,200,000	-65,522,000	-68,444,000	-64,843,000	-53,549,000	-54,179,000	-10,021,000	-47,956,000	-47,374,000	-54,115,000	-67,638,000	50,534,000	63,650,000	-83,709,000	-9,044,000	-75,304,000	-111,362,000	20,557,000	-55,676,000	-47,022,000	-49,290,000	-45,000,000	-53,097,000	-99,852,000	-51,379,000	-64,346,000	-40,000,000	-54,015,000	-50,594,000	774,553,000	-65,015,000	-100,232,000	-47,449,000	167,540,000	-25,898,000	-44,719,000	-42,887,000	36,056,000	-96,695,000	42,602,000	30,737,000	-17,797,000	-30,077,000	-77,120,000	-17,000,000	-27,920,000	658,133,000	-17,999,000	-16,992,000	-22,708,000	-28,574,000
cash and cash equivalents - beginning of year
cash and cash equivalents - end of year
acquisition and other
payments of debt costs														0
decrease in cash and cash equivalents					-12,213,000																																												-14,611,000				-7,343,000
deferred income taxes						8,178,000	5,171,000	5,449,000	4,272,000	9,810,000	2,998,000	1,213,000	-1,317,000	3,657,000	1,763,000	5,876,000	10,658,000	4,314,000	-2,491,000	6,147,000	6,469,000	1,556,000	1,621,000	4,206,000	-43,863,000	2,970,000	-6,416,000	6,755,000	-12,236,000	-273,171,000	7,096,000	9,225,000	6,752,000	-1,928,000	-942,000	-9,660,000	14,561,000	9,606,000	10,449,000	11,536,000	7,140,000	8,751,000	5,906,000	-2,442,000	6,797,000	9,526,000	3,588,000	5,315,000	7,076,000	6,472,000	1,359,000	2,776,000	3,186,000	2,038,000	4,338,000
loss on extinguishment of debt													0	0							0																17,519,000	0	0	451,000		3,274,000												300,000
proceeds from refinancing of term loan													0	0
acquisition of akorn
changes in operating assets and liabilities
escrow receipt																					0
acquisitions													-132,000
proceeds from issuance of senior notes
repayment of senior notes
gain on divestitures
proceeds from divestitures																																	0
acquisition of tradename
proceeds from issuance of 5.125% senior notes
repayment of 5.375% senior notes
interest expense relating to finance lease liability																			59,000	50,000
interest expense relating to rou assets																					50,000
lease termination costs																													0																	0	0
other non-cash items
changes in operating assets and liabilities, net of effects from acquisitions and divestitures:
prepaid expenses and other assets
proceeds from issuance of 2016 senior notes
proceeds from issuance of 2019 senior notes
repayment of 2013 senior notes
payments of debt origination costs																																	-11,131,000	0	0	-9,000	-7,617,000	0	-39,000	-4,172,000
gain on divestiture																										0
proceeds from divestiture																										0
(gain) loss on divestitures
excess tax benefits from share-based awards																														0	168,000	302,000	100,000	0	250,000	550,000	110,000	0	250,000	1,600,000	950,000	-75,000	375,000	898,000	452,000
changes in operating assets and liabilities, net of effects from acquisitions:
pension contribution
proceeds from the sale of property, plant and equipment
proceeds from working capital arbitration settlement
acquisition of c.b. fleet, less cash acquired
acquisition of c.b. fleet escrow receipt
proceeds from issuance of term loan
write-off of indemnification asset
pension and deferred compensation contribution																													-106,000
acquisition of fleet escrow receipt
loss on divestitures
gain on sale or disposal of property and equipment
long term income taxes payable
premium payment on 2012 senior notes
acquisition of dentek, less cash acquired
repayment of 2012 senior notes
borrowings under bridge term loans
repayments under bridge term loans
proceeds from restricted stock exercises																																					0	0	0	544,000	57,000
loss on disposals of property and equipment																														49,000	971,000	490,000
noncurrent assets and liabilities																														-358,000	342,000	-287,000
acquisition of fleet escrow payment																														0	0	970,000
proceeds from the sales of property, plant and equipment
proceeds from dentek working capital arbitration settlement																																	0
proceeds from sales of intangible assets
loss on divestitures and sales of property and equipment																																	13,000
gain on sale of asset																																								-36,000
purchases of property and equipment																																	-1,042,000	-531,000	-509,000	-895,000	-1,028,000	-857,000	-903,000	-780,000	-496,000	-106,000	-339,000	-955,000	-1,364,000	-1,346,000	-3,656,000	-4,068,000	-1,198,000
proceeds from the sale of property and equipment																																					0	0	0	344,000			0	1,000	2,000
proceeds from sale of asset
proceeds from insight pharmaceuticals working capital arbitration settlement																																					0
acquisition of insight pharmaceuticals, less cash acquired
acquisition of the hydralyte brand																																									-77,991,000
term loan repayments resulting from refinancing
proceeds from the sales of property and equipment
gain on sales of intangible assets and property and equipment
changes in operating assets and liabilities, net of effects from acquisitions
gain on sale of assets																																				55,453,000
premium payment on 2010 senior notes																																										-2,759,000
(gain) loss on sale or disposal of property and equipment																																					1,000					0
proceeds from sale of business
acquisition of care pharmaceuticals, less cash acquired																																										0	0
proceeds from issuance of 2013 senior notes
repayment of 2010 senior notes																																										-48,290,000
term loan borrowings
amortization of deferred financing costs																																									851,000	1,079,000	4,048,000	1,083,000	892,000	1,612,000	6,160,000	1,012,000	1,048,000	783,000	282,000	282,000	283,000	255,000	527,000
amortization of debt discount																																									144,000	295,000	2,317,000	453,000	345,000	740,000	3,080,000	408,000	404,000	343,000	229,000	229,000	229,000	142,000
proceeds from sale of property and equipment																																																0	15,000
proceeds from the sale of phazyme brand
acquisition of brands from gsk purchase price adjustments																																														0	0	0	-226,000
payment of deferred financing costs																																									-74,000	-533,000	-6,658,000	5,000	-280,000									-112,000
(gain) on sale or disposal of property and equipment
proceeds from escrow of blacksmith acquisition																																																		0	0
acquisition of brands from gsk
proceeds from issuance of 2012 term loan
repayment of 2010 term loan
repayment of 2012 term loan
proceeds from the sale of the phazyme brand
proceeds from the issuance of 2013 senior notes
repayments of long-term debt																																											-140,000,000				-97,500,000	-25,000,000	-45,000,000
(gain) loss on sale or disposal of equipment																																												-1,000	-2,000
loss on sale of discontinued operations
loss on disposal of equipment																																														52,000	0	30,000	21,000
proceeds from sale of discontinued operations
acquisition of blacksmith, net of cash acquired
acquisition of dramamine
proceeds from issuance of 2012 term loan and 2010 term loan
repayment of long-term debt																																																		33,000,000	-18,000,000	-17,000,000	-23,000,000	-28,462,000
shares surrendered as payment of tax withholding																																																		0	0	0	-271,000
cash - beginning of year
cash - end of year
gain on sale of discontinued operations
impairment of goodwill and intangible assets
purchases of equipment																																																		-248,000	-51,000	-231,000	-76,000	-130,000
acquisition of gsk brands
proceeds from issuance of debt
increase in cash																																																						-7,991,000	8,611,000
inventories held for sale
proceeds from issuance of senior term loan
business acquisition purchase price adjustments
1.
loss on disposition of equipment																																																						125,000
income taxes payable
cash - beginning of period																																																						41,097,000	5,334,000
cash - end of period																																																						33,106,000	13,945,000
machinery																																																						5,000
computer equipment																																																						3,000
furniture and fixtures																																																						7,000
changes in operating assets and liabilities, net of effects of purchases of businesses
account payable – related parties
accrued expenses
purchase of equipment
purchase of business, net of cash acquired
proceeds from the issuance of notes
repayment of notes
proceeds from the issuance of preferred and common units
additional costs associated with initial public offering
supplemental cash flow information
fair value of assets acquired, net of cash acquired
fair value of liabilities assumed
purchase price funded with non-cash contributions
cash paid to purchase business

We provide you with 20 years of cash flow statements for Prestige Consumer Healthcare stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Prestige Consumer Healthcare stock. Explore the full financial landscape of Prestige Consumer Healthcare stock with our expertly curated income statements.

The information provided in this report about Prestige Consumer Healthcare stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.